Here's Why you Should Retain Veeva Systems Stock in Your Portfolio Now

Zacks12-17

Veeva Systems Inc. VEEV is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid third-quarter fiscal 2025 performance and strategic ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492455965?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/46gFT4Y7HZuuo2Xj6ImXmw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/35df2d293bff824e6b9f2134b8f740a3","is_english":true,"pubTime":"2024-12-17 21:04","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2492455965","market":"us","top_or_hot":-1,"title":"Here's Why you Should Retain Veeva Systems Stock in Your Portfolio Now","media":"Zacks","content":"<div>\n<p>Veeva Systems Inc. VEEV is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid third-quarter fiscal 2025 performance and strategic ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-retain-veeva-systems-130400096.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why you Should Retain Veeva Systems Stock in Your Portfolio Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why you Should Retain Veeva Systems Stock in Your Portfolio Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-17 21:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/heres-why-retain-veeva-systems-130400096.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Veeva Systems Inc. VEEV is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid third-quarter fiscal 2025 performance and strategic ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-retain-veeva-systems-130400096.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2357305700.SGD","symbol_name":"Allianz Global Artificial Intelligence ET H2-SGD","start_time":0,"source_url":"https://finance.yahoo.com/news/heres-why-retain-veeva-systems-130400096.html","article_id":"2492455965","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/46gFT4Y7HZuuo2Xj6ImXmw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/35df2d293bff824e6b9f2134b8f740a3"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492455965","pubTimestamp":1734440640,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Veeva Systems Inc.VEEV is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid third-quarter fiscal 2025 performance and strategic deals, is expected to contribute further. Stiff competition and rising operational costs persist.This Zacks Rank #3  company’s shares have risen 16.7% in the year-to-date period compared with 40.2% growth of theindustry. The S&P 500 Composite has risen 27.7% during the said time frame.The renowned provider of cloud-based software applications and data solutions for the life sciences industry has a market capitalization of $37.14 billion. The company projects 26.2% growth for the next five years and expects to maintain its strong performance in the future. It delivered a trailing four-quarter average earnings surprise of 6.92%.Robust Product Portfolio:We are optimistic about Veeva Systems’ unique solutions, which include Veeva Vault, Veeva CRM , Veeva Network and Veeva OpenData.Strategic Deals:","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU2458330243.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A-H1\" (SGDHDG) ACC","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","BK4534":"瑞士信贷持仓","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","IE00BJTD4V19.USD":"NEUBERGER BERMAN US LONG SHORT EQUITY \"A1\" (USD) ACC","LU0889565833.HKD":"FRANKLIN TECHNOLOGY \"A\" (HKD) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1803068979.SGD":"FTIF - Franklin Technology A (acc) SGD-H1","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","BK4082":"医疗保健设备","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","ARAY":"精确射线","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU0109392836.USD":"富兰克林科技股A","BK4588":"碎股","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU0240878834.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" (USD) INC AV","MASI":"麦斯莫医疗","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","BK4561":"索罗斯持仓","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","AXGN":"AxoGen Inc.","BK4505":"高瓴资本持仓","IE00BQXX3C00.GBP":"GUINNESS GLOBAL INNOVATORS \"C\" (GBP) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","BK4548":"巴美列捷福持仓","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0251131958.USD":"FIDELITY AMERICA \"A\" (USD) ACC","LU2286300806.USD":"Allianz Cyber Security AT Acc USD","LU1951200564.SGD":"Natixis Thematics AI & Robotics Fund R/A SGD","IE00BJTD4N35.SGD":"Neuberger Berman US Long Short Equity A1  Acc SGD-H","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","VEEV":"Veeva Systems Inc.","BK4023":"应用软件","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","BK4532":"文艺复兴科技持仓"},"translate_title":"这就是为什么您现在应该在您的投资组合中保留Veeva Systems股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXGN":1,"VEEV":1,"MASI":1,"ARAY":1},"content_text":"Veeva Systems Inc. VEEV is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid third-quarter fiscal 2025 performance and strategic deals, is expected to contribute further. Stiff competition and rising operational costs persist.\nThis Zacks Rank #3 (Hold) company’s shares have risen 16.7% in the year-to-date period compared with 40.2% growth of the industry. The S&P 500 Composite has risen 27.7% during the said time frame.\nThe renowned provider of cloud-based software applications and data solutions for the life sciences industry has a market capitalization of $37.14 billion. The company projects 26.2% growth for the next five years and expects to maintain its strong performance in the future. It delivered a trailing four-quarter average earnings surprise of 6.92%.\nImage Source: Zacks Investment Research\nReasons Favoring VEEV’s Growth\nStrong Q3 Results: Veeva Systems exited the third quarter of fiscal 2025 with better-than-expected results. The uptick in the overall top line and bottom line and robust performance by the Subscription services segment during the quarter were impressive. Per management, more than 30 customers are now live on Vault CRM, and the seven migrations from Veeva CRM to Vault CRM are on track for completion by year-end.\nIn the fiscal third quarter, Veeva Systems’ gross profit improved 16.9% year over year to $524.8 million. The gross margin expanded 230 basis points (bps) to 75.1%. The operating margin in the fiscal third quarter expanded by a huge 510 bps to 25.9%.\nRobust Product Portfolio: We are optimistic about Veeva Systems’ unique solutions, which include Veeva Vault, Veeva CRM (customer relationship management), Veeva Network and Veeva OpenData.\nVeeva Systems continues to expand its product portfolio with new launches. In December, the company announced the latest release of Vault CRM Suite. Vault CRM Campaign Manager is also now available as part of Vault CRM Suite, which is likely to help companies realize the vision of connected sales, marketing, and medical for streamlined, customer-centric engagement.\nIn November, Veeva Systems unveiled Vault CRM Bot and Vault CRM Voice Control, the two new Generative Artificial Intelligence capabilities in Vault CRM, likely to be introduced next year. In August, the company reached a significant milestone on its path to connect sales, marketing, medical records and services to enable true customer centricity with the release of Vault CRM Service Center.\nVeeva Systems also added 13 new Vault CRM customers in the fiscal third quarter. In September, VEEV commented on the release of Veeva Site Connect, which is part of the Veeva Clinical Platform. Veeva Site Connect plays a critical role as the industry simplifies and standardizes site collaboration, and seven of the top 20 biopharma companies have already adopted it to streamline trials.\nStrategic Deals: We are upbeat about Veeva Systems’ recent few collaborations. In November, VEEV announced that Boehringer Ingelheim is set to commit to moving to Veeva Vault CRM. Boehringer Ingelheim seeks to expand on its existing Veeva Commercial Cloud solutions and One Medicine and Amplify platforms, which connect development processes and data on Veeva Development Cloud. In October, Veeva Systems and Walgreens Boots Alliance announced a long-term strategic partnership to help life sciences companies improve patient outcomes. Through this collaboration, Walgreens will likely use Veeva Systems’ Data Cloud and Clinical Platform to connect its extensive network of community locations with diverse patient populations, aiming to simplify access to clinical research.\nIn June, the company announced a partnership with Vita Global Sciences that is likely to help the latter improve its clinical data management processes and collaborations with key trial stakeholders. The latest adoption of Veeva Vault electronic data capture, part of the Veeva Clinical Platform, is likely to boost the Veeva Development Cloud business.\nFactors That May Offset the Gains of VEEV\nStiff Competition: Veeva Systems operates in a highly competitive market. In new sales cycles within the company’s largest product categories, it competes with other cloud-based solutions from providers, such as IQVIA Inc., that make applications geared toward the life sciences industry. VEEV’s Commercial Cloud and Veeva Vault application suites also compete to replace client server-based legacy solutions offered by companies like Oracle, Microsoft Corporation and other smaller application providers.\nRising Costs: Veeva Systems has been experiencing rising operating costs over the past few months. Sales and marketing expenses for the third quarter of fiscal 2025 increased 1.9% year over year. Management expects sales and marketing expenses to increase in fiscal 2025, primarily due to employee-related expenses as the company raises its headcount to support its sales and marketing efforts associated with its product offerings and continued expansion of its sales capacity across all its solutions. In the fiscal third quarter, the total operating expenses increased 7.2% year over year. Veeva Systems expects operating expenses to increase in fiscal 2025, primarily due to employee compensation-related costs. \nEstimate Trend\nVeeva Systems is witnessing a positive estimate revision trend for fiscal 2025. In the past 60 days, the Zacks Consensus Estimate for earnings per share (EPS) has moved 18 cents north to $6.41.\nThe Zacks Consensus Estimate for fourth-quarter fiscal 2025 revenues is pegged at $698.1 million, indicating an 10.7% improvement from the year-ago quarter’s reported number. EPS estimate is pinned at $1.57, implying 13.8% improvement year over year.\nKey Picks\nSome better-ranked stocks in the broader medical space are Masimo MASI, Accuray ARAY and AxoGen AXGN.\nMasimo, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated growth rate of 11.8% for 2025. You can see the complete list of today’s Zacks #1 Rank stocks here.\nMASI’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 17.10%. Its shares have risen 49.4% compared with the industry’s 6.7% growth year to date.\nAccuray, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 1200% for 2025. Its earnings missed estimates in three of the trailing four quarters and met in one, delivering an average negative surprise of 141.97%.\nARAY’s shares have lost 32.2% against the industry’s 6.7% growth year to date.\nAxoGen, carrying a Zacks Rank of 2 at present, has an estimated earnings growth rate of 252% for 2025. It delivered a trailing four-quarter average earnings surprise of 91.11%.\nAXGN’s shares have risen 111% year to date compared with the industry’s 6.7% growth.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAccuray Incorporated (ARAY) : Free Stock Analysis Report\nMasimo Corporation (MASI) : Free Stock Analysis Report\nAxoGen, Inc. (AXGN) : Free Stock Analysis Report\nVeeva Systems Inc. (VEEV) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492455965"}